Phaseline

Targets › TOP2A

TOP2A (DNA topoisomerase 2-alpha): drug programs, companies and trials

24 programs from 18 companies in 67 trials: 32 Phase 2, 21 Phase 1, 13 Phase 3, 1 Phase 4; Oncology, Hematology, Infectious disease; next expected readout Dec 2026.

Key decatenating enzyme that alters DNA topology by binding to two double-stranded DNA molecules, generating a double-stranded break in one of the strands, passing the intact strand through the broken strand, and religating the broken strand. May play a role in regulating the period length of BMAL1 transcriptional oscillation (By similarity). (UniProt, P11388)

Open in Phaseline: the race on TOP2A, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Hospital JP GarrahanABVD
Combination chemotherapy: Doxorubicin (topoisomerase II inhibitor), Bleomycin (DNA damagin
TOP2A, CHEK1Phase 4Pediatric Hodgkin's DiseaseOct 2027
European Organisation for Research and Treatment of Cancer - EORTCEpirubicin (EpiADM)
Anthracycline; topoisomerase II inhibitor
TOP2APhase 3Retroperitoneal SarcomaApr 2027
Institute of Hematology & Blood Diseases Hospital, Chinadaunorubicin
DNA topoisomerase II alpha inhibitor
TOP2APhase 3AML; CEBPA Double Mutation; Acute Leukemia of Ambiguous LineageJun 2027
Children's Oncology GroupDaunorubicin Hydrochloride
DNA topoisomerase II alpha inhibitor
TOP2APhase 3Acute Myeloid LeukemiaJun 2027
IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italyepirubicin hydrochloride
Anthracycline; intercalates into DNA and inhibits topoisomerase II
TOP2APhase 3Breast CancerDec 2027
CSPC ZhongQi Pharmaceutical TechnologyMitoxantrone
DNA topoisomerase II alpha inhibitor
TOP2APhase 3Peripheral T Cell Lymphoma; Acute Myeloid Leukaemia; B-cell Acute Lymphoblastic Leukemia; Soft Tissue Sarcoma …Dec 2027
Stichting Hemato-Oncologie voor Volwassenen NederlandDexrazoxane
DNA topoisomerase II inhibitor
TOP2A, TOP2BPhase 3DLBCL - Diffuse Large B Cell LymphomaDec 2028
European Organisation for Research and Treatment of Cancer - EORTCABVD regimen
Combination of doxorubicin, bleomycin, vinblastine, and dacarbazine - multi-modal chemothe
Tubulin, TOP2A, MYCPhase 3Lymphoma–
European Organisation for Research and Treatment of Cancer - EORTCBEACOPP regimen
Combination of bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbaz
TOP2A, TubulinPhase 3Lymphoma–
European Organisation for Research and Treatment of Cancer - EORTCdoxorubicin hydrochloride
DNA topoisomerase II alpha inhibitor
TOP2APhase 3Lymphoma–
National Cancer Institute (NCI)Daunorubicin Hydrochloride
DNA topoisomerase II alpha inhibitor
TOP2APhase 2Acute Myeloid LeukemiaFeb 2027
National Cancer Institute (NCI)Doxorubicin Hydrochloride
DNA topoisomerase II alpha inhibitor
TOP2APhase 2Fallopian Tube High Grade Serous Adenocarcinoma; Metastatic Dedifferentiated Liposarcoma; Ann Arbor Stage III Non-Hodgkin LymphomaMay 2027
ImmunityBioAldoxorubicin
DNA topoisomerase II alpha inhibitor
TOP2APhase 2Pancreatic CancerMay 2027
Fred Hutchinson Cancer CenterIdarubicin
DNA topoisomerase II alpha inhibitor
TOP2APhase 2Acute Leukemia of Ambiguous Lineage; Acute Myeloid LeukemiaJun 2027
M.D. Anderson Cancer CenterDexrazoxane Hydrochloride
DNA topoisomerase II inhibitor
TOP2A, TOP2BPhase 2Acute Myeloid LeukemiaDec 2027
M.D. Anderson Cancer CenterIdarubicin
DNA topoisomerase II alpha inhibitor
TOP2APhase 2Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11; Acute Biphenotypic Leukemia; Acute Myeloid LeukemiaDec 2027
Navy General Hospital, Beijingidarubicin
DNA topoisomerase II alpha inhibitor
TOP2APhase 2Primary Central Nervous System LymphomaDec 2028
Second Affiliated Hospital of Guangzhou Medical Universityidarubicin
DNA topoisomerase II alpha inhibitor
TOP2APhase 2Hepatic Cancer; Lung CancerDec 2028
University Hospital, AngersVosaroxin
Topoisomerase II inhibitor (quinolone derivative)
TOP2APhase 2Acute Myeloid Leukemia (AML)Jan 2032
M.D. Anderson Cancer CenterEtoposide phosphate
DNA topoisomerase II alpha inhibitor
TOP2APhase 2LymphomaJan 2034
CNS PharmaceuticalsBerubicin
DNA topoisomerase II inhibitor
TOP2A, TOP2BPhase 2Glioblastoma Multiforme, Adult–
Princess Maxima Center for Pediatric OncologyVyxeos®/CPX-351
Liposomal daunorubicin and cytarabine combination
TOP2APhase 1Relapsed Pediatric AMLDec 2026
City of Hope Medical CenterDoxorubicin Hydrochloride
DNA topoisomerase II alpha inhibitor
TOP2APhase 1FIGO Stage IVA Ovarian Cancer; AIDS-Related Burkitt LymphomaJan 2027
SkinJectDoxorubicin-containing MNA
Topoisomerase II inhibitor delivered via dissolvable microneedle array
TOP2APhase 1Basal Cell Carcinoma–

Conditions

Acute Myeloid Leukemia (8) Lymphoma (7) Peripheral T Cell Lymphoma (4) Non Hodgkin Lymphoma (4) Acute Leukemia of Ambiguous Lineage (2) AML (2) Relapse Acute Myeloid Leukemia (2) Acute Biphenotypic Leukemia (2) Primary Central Nervous System Lymphoma (2) CEBPA Double Mutation (1) Fallopian Tube High Grade Serous Adenocarcinoma (1) Metastatic Dedifferentiated Liposarcoma (1)

Modalities

mixed (13), small molecule (9), antibody (1)

Companies

European Organisation for Research and Treatment of Cancer - EORTC (4) M.D. Anderson Cancer Center (3) National Cancer Institute (NCI) (2) Fred Hutchinson Cancer Center (1) Institute of Hematology & Blood Diseases Hospital, China (1) SkinJect (1) CNS Pharmaceuticals (1) CSPC ZhongQi Pharmaceutical Technology (1) University Hospital, Angers (1) Navy General Hospital, Beijing (1) ImmunityBio (1) Children's Oncology Group (1) City of Hope Medical Center (1) Second Affiliated Hospital of Guangzhou Medical University (1) Stichting Hemato-Oncologie voor Volwassenen Nederland (1) IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy (1) Princess Maxima Center for Pediatric Oncology (1) Hospital JP Garrahan (1)

Related targets

TOP2B (3) Tubulin (2) MYC (1) CHEK1 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.